Following RNA processing into cellular aging

# Following RNA processing into cellular aging OCTOBER 15, 2026 | LONGEVITY SPECIAL Turning up a single gene made aged cells look younger in the lab, and aged mice with the gene switched on had a longer median lifespan. That is the finding from a new study in Nature Aging. The publication type is not stated in the material we had. It is early work in cells and mice, and it is not a treatment for people. The lifespan gain is described as associated with the gene, not proven to be caused by it. A gene involved in RNA splicing offers another route into the biology of aging cells. The interest lies in how the cell's handling of information might relate to its function. The gene is SRSF1. It helps process RNA, the working copies the body makes from DNA. According to the study's abstract, the researchers first built a "transcriptomic age" predictor in human skin cells called fibroblasts. It reads which genes are active in a cell and estimates how old the cell looks. They then ran a screen, a cDNA overexpression screen, switching on genes in aged cells to see which pushed the cells toward a younger pattern. SRSF1 was the standout. The abstract says it produced strong youthful gene-activity patterns without the cells losing their identity. That point matters. Earlier approaches to reversing aging in cells, which use proteins called Yamanaka factors, can raise concerns about toxicity and efficacy, the abstract notes, and those concerns limit their use in living animals. In cell experiments, switching on SRSF1 restored youthful traits. The abstract reports less senescence, which is when cells stop dividing but linger and cause trouble. It also reports less protein-handling stress and less inflammatory signaling. The mouse result is the headline number, but it comes from small groups. In aged mice with SRSF1 switched on, frailty progressed 44% less, according to the abstract. Median lifespan was 14% longer. The groups held 9 to 10 mice each. The abstract describes the lifespan gain as "associated with" SRSF1 expression, which is careful wording. With groups this small, the results need to be repeated before anyone leans on them. This is the weakest part of the story. The abstract also says the work implicates SRSF1 in aging in worms as well as mice. The authors call it a "conserved regulator of aging," meaning it appears to play a similar role across species. They describe it as a promising target. Only the abstract was available to us, so we cannot report details such as how the gene was delivered, how long effects lasted or whether any side effects appeared. The abstract also does not list the authors or their institutions, and we could not confirm where the work was done. The abstract's summary names Plesa, Jung and colleagues as the researchers behind the screen. We could not verify further details about the team, and we are not relying on press commentary for any claims here. Any views researchers hold about what the work means are opinions, not findings. FOR YOU What does this mean for personal health? Not much yet. Nothing here shows that people can slow aging by targeting splicing. It does not support splicing-related supplements, and it does not support tests that claim to measure splicing activity. SRSF1 was raised artificially in these experiments. Nothing in the study suggests a pill or a diet can do the same thing safely. Mouse lifespan results also often fail to carry over to people. Do not start or stop any medication, treatment or supplement without talking to your clinician. The value of the work is in the direction it points. It suggests that resetting how cells process RNA could be a way to push back on aging signs without erasing what a cell is. Whether that holds up is the open question. Watch for larger mouse studies from independent labs, safety data on raising SRSF1 over time, and any sign of how the gene works. Those steps would come well before any human trial. The next experiments need to clarify the mechanism, reproducibility, and safety. A more detailed understanding would be useful even before any therapeutic application emerges. Sources: Nature Aging (2026), Nature Aging (publisher page) Nature Aging (2026),: https://doi.org/10.1038/s43587-026-01234-8 Nature Aging (publisher page): https://www.nature.com/articles/s43587-026-01234-8 ---